IGF-1 LR3: Escaping the Binding Proteins, and What That Means at the Bench

IGF-1 LR3 is an 83-amino-acid recombinant variant of human insulin-like growth factor 1, altered in two deliberate ways: position 3 carries arginine instead of glutamate, and a 13-residue peptide is added at the N-terminus. Both changes serve one aim — stripping away the affinity for the IGF binding proteins that ordinarily sequester native IGF-1 — while barely affecting how the molecule binds the IGF-1 receptor. The outcome is a growth factor that remains available whether it is in buffer or in medium containing serum, which is why cell-culture and receptor-signalling labs were using it routinely long before research-chemical suppliers started listing it.

IGF-1 LR3 is available from us freeze-dried, in 0.1 mg and 1 mg vials, as part of the IGF and muscle peptides range.

Defining IGF-1 LR3

The name describes the chemistry. Read "LR3" as Long R3: the leader sequence makes it "long", and the substituted arginine in third position gives "R3". Native IGF-1, from which it derives, is a 70-residue single-chain protein resembling proinsulin in structure; the liver secretes most of it under the control of growth hormone, and it signals via IGF-1R, which belongs to the receptor tyrosine kinase family. Circulating IGF-1 is nearly all carried by six different IGF binding proteins that regulate its availability and keep the unbound half-life to only minutes.

IGF-1 LR3 is made by recombinant expression rather than by solid-phase synthesis — with 83 residues and a mass of 9,117.60 g/mol it is really a small protein, too long to assemble residue by residue in any practical way. It is registered under CAS 946870-92-4, has the formula C400H625N111O115S9, and keeps the three disulfide bonds that hold the native IGF-1 fold together.

Origin and structure

Neither change targets the receptor interface; both target the interface with the binding proteins. Glu3 lies in the N-terminal region that makes a key charge-based contact with the binding proteins, and replacing it with arginine flips that local charge — reported to reduce affinity for the binding proteins roughly a hundredfold. The 13-residue leader (MFPAMPLSSLFVN) adds steric hindrance at the same surface and also raises the isoelectric point of the molecule, changing its solution behaviour.

The part of the protein that contacts the receptor is exactly what the changes avoid. The residues IGF-1R recognises sit on a different face of the protein, leaving LR3 fully agonistic. Cell-culture studies routinely find it far more potent in practice than the unmodified factor — the reason being availability, not stronger binding: far more of the analogue is unbound and free to engage its target.

The proposed mechanism

Its target, IGF-1R, is a disulfide-bonded α2β2 receptor tyrosine kinase closely related to the insulin receptor. Ligand binding triggers autophosphorylation in the kinase domain of the β-subunits and recruits insulin receptor substrate (IRS) proteins. Two principal cascades then diverge: PI3K–Akt–mTOR, associated in published work with protein-synthesis and survival endpoints, and Ras–Raf–MEK–ERK, associated with proliferation endpoints. These are the pathways researchers measure when assessing responses in myoblast cultures.

Two mechanistic caveats should shape any design. First, IGF-1R can pair with the insulin receptor to form hybrids, and IGF-1 analogues retain measurable binding to insulin receptor isoform A — selectivity is a matter of degree, not all-or-nothing. Second, by evading the binding proteins, the analogue removes a layer of regulation that is part of normal IGF-1 biology. A study with IGF-1 LR3 is therefore deliberately looking at unbuffered receptor activation: well suited to signalling questions, less faithful to physiological IGF-1 exposure.

What has been studied

Cell culture and bioprocessing

Its longest-standing and largest use is as an additive to serum-free media. The bioprocessing literature widely describes the Long R3 form of IGF-1 replacing insulin in CHO and hybridoma cultures; because it ignores the binding proteins those cells secrete, it stays active in the medium longer than native IGF-1 does. This is industrial-scale in-vitro use with well-understood results.

Myoblast and skeletal muscle signalling

In C2C12 cells and primary myoblasts, the analogue has been used to study proliferation, differentiation, Akt phosphorylation and hypertrophy signalling in cultured myotubes. These are measurements in cells, and the literature does not justify extrapolating them to outcomes in whole animals or people.

Rodent growth and metabolic models

The bulk of animal work with Long R3 IGF-1 was done in the 1990s. Rat studies reported greater growth-promoting activity than an equal number of moles of native IGF-1, as the binding-protein argument would predict. Metabolic studies also recorded drops in blood glucose, reflecting the residual cross-reactivity with the insulin receptor mentioned earlier.

Comparative analogue work

Researchers frequently compare IGF-1 LR3 next to IGF-1 DES (1-3), a shortened analogue that escapes the binding proteins by removing residues rather than substituting one. In settings where IGFBPs are being actively cleaved, the two behave differently, so the choice has real experimental consequences — see our IGF-1 LR3 vs IGF-1 DES comparison, and the background article on why these modified forms were created.

Presentations available

The 0.1 mg vial is sized for single-plate cell work and receptor assays at ng/mL concentrations; the 1 mg vial is for longer series that should use a single lot throughout. Our IGF-1 LR3 buying guide covers what to check when sourcing.

Reconstitution and storage at the bench

A recombinant growth factor needs different handling from a short synthetic peptide. IGF-1 LR3 dissolves badly at neutral pH, so manufacturers' protocols dissolve it first in weak acid — typically 10 mM HCl or 0.1% acetic acid — and only then dilute it into buffer or medium. Putting it straight into a neutral buffer risks partial dissolution and aggregation, which shows up as inconsistent activity rather than as anything you can see in the tube.

The maths is easy — 1 mg made up to 1 mL is 1 mg/mL (1,000 mcg/mL), so each 0.1 mL holds 100 mcg — but culture stocks are usually diluted several steps further. Any protein at low concentration sticks to glass and plastic, so working stocks below about 10 mcg/mL normally include a carrier such as 0.1% BSA. Our reconstitution guide gives the general procedure.

Keep lyophilized vials sealed at −20 °C or colder, protected from light and moisture. Aliquot reconstituted material at once and freeze it; for a 9 kDa protein held together by three disulfide bridges, nothing costs more activity than repeated freezing and thawing. Fuller guidance appears in how to store peptides.

Purity, the COA and how to read it

For a protein made by recombinant expression, the certificate should be read differently than for a peptide made by synthesis. Purity by HPLC is still reported first, yet with a protein of 83 residues two other entries tell you more. The mass-spec value should read 9,117.60 g/mol, which rules out native IGF-1 (7,649 g/mol). An SDS-PAGE image, if supplied, shows aggregated and truncated species that reversed-phase HPLC can mask. For cell-culture work the level of endotoxin is important as well, since the protein is usually expressed in bacteria. For how the sections relate, see the COA reading guide for peptides.

Regulatory position

IGF-1 LR3 holds no medicinal marketing authorisation in either the EU or the United States. Mecasermin — recombinant human IGF-1 — is an authorised prescription therapy for a rare disorder of growth, but it is a separate molecule and LR3 cannot stand in for it. Sports anti-doping codes prohibit IGF-1 along with all of its analogues.

Related molecules and further reading

The closest related products are IGF-1 DES (1-3), the truncated analogue, and MGF, a peptide derived from the E domain of the IGF-1 Ec splice variant; MGF does not activate the receptor and answers a different research question. For the wider landscape, see our peptides for muscle growth research overview.

Matching catalogue section: IGF & Muscle Peptides